Compare SOPH & CION Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SOPH | CION |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 374.1M | 384.8M |
| IPO Year | 2021 | 2011 |
| Metric | SOPH | CION |
|---|---|---|
| Price | $4.98 | $6.68 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 2 | 1 |
| Target Price | ★ $7.50 | $7.00 |
| AVG Volume (30 Days) | 88.5K | ★ 547.6K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 15.96% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.09 | N/A |
| Revenue Next Year | $19.57 | N/A |
| P/E Ratio | ★ N/A | $17.55 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.59 | $6.50 |
| 52 Week High | $5.70 | $10.93 |
| Indicator | SOPH | CION |
|---|---|---|
| Relative Strength Index (RSI) | 51.48 | 42.09 |
| Support Level | $4.54 | $6.55 |
| Resistance Level | $5.29 | $7.27 |
| Average True Range (ATR) | 0.28 | 0.17 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 71.64 | 28.57 |
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
CION Invt Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The Companies portfolio is comprised of investments in senior secured debt, including first lien loans, second lien loans, and unitranche loans, and, to a lesser extent, collateralized securities, structured products and other similar securities, unsecured debt, and equity, of private and thinly-traded U.S. middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation for investors.